NCT01471548View on ClinicalTrials.gov

Phase I Dose Escalating Study of TKI258

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

TKI258

Trial Locations (2)

569-8686

Novartis Investigative Site, Takatsuki

350-1241

Novartis Investigative Site, Hidaka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY